These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A personal history of the CAMPATH-1H antibody.
    Author: Waldmann H.
    Journal: Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490.
    Abstract:
    The recent licensing of CAMPATH-1H (alemtuzumab) for the treatment of patients with refractory chronic lymphocytic leukemia has been the culmination of a long journey. This success is in large part due to the persistence, dedication, and commitment of a large number of academic collaborators. The first breakthrough was the identification of CAMPATH-1M, an isotype directed against CD52, and extremely efficient at lysing target cells in the presence of human complement, but limited in vivo by the rate of complement biosynthesis. The search for a monoclonal antibody that was more efficient in vivo found the rare class-switching variant CAMPATH-1G, which is able to kill target cells by antibody-dependent cell-mediated cytotoxicity. Construction of the humanized form of the antibody, CAMPATH-1H, and the development of resources to manufacture clinical-grade material, further expedited many studies across the world in leukemia and lymphoma as well as in marrow transplantation, autoimmune disorders, and kidney transplantation. Such studies have taught us a lot about the diseases themselves, as well as offering the prospect of harnessing immunological tolerance processes to facilitate a whole new approach to immunosuppression.
    [Abstract] [Full Text] [Related] [New Search]